

Original Research Article

Alterations in Indices of RBC and Iron Metabolism in Hypothyroidism - A Cross-Sectional StudyMousumi Sharma¹, Dilutpal Sharma², Debadyuti Sahu³, Prabhat⁴

¹Associate Professor, Department of Pathology, Integral Institute of Medical Science and Research, Lucknow, UP, India. ²Associate Professor, ³Post-MD PhD Scholar cum Senior Resident, Department of Biochemistry, King George Medical University, Lucknow, UP, India. ⁴Assistant Professor Department of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, UP, India.

Corresponding Author:

Debadyuti Sahu, Post-MD PhD Scholar cum Senior Resident, Department of Biochemistry, King George Medical University, Lucknow, UP, India.

E-mail: drdsahu1985@gmail.com

How to cite this article:

Mousumi Sharma, Dilutpal Sharma, Debadyuti Sahu, Prabhat, et al. Alterations in Indices of RBC and Iron Metabolism in Hypothyroidism - A Cross-Sectional Study. Indian J Pathol Res Pract 2020;9(2 Part II):197-205.

Abstract

Background: Thyroid hormones regulate metabolic rate and stimulate hematopoiesis via multiple mechanisms. Alterations in various hematological parameters have been reported in various thyroid disorders. Hypothyroidism is the most common thyroid disease.

Objectives: To evaluate various erythrocyte indices and indices of iron metabolism in (subclinical and overt) hypothyroid cases and compare with control (euthyroid) group.

Materials and Methods: Laboratory data and medical records of patients were retrieved. Patients were grouped as 'overt hypothyroid' (TSH >5.5 µIU/ml and reduced serum T4 and/or T3); 'subclinical hypothyroid' (TSH 4.0-5.5 µIU/ml with normal thyroxin) and euthyroid (control) group (TSH 0.03-4.0 µIU/ml with normal serum THs). Complete blood count (CBC) and iron indices data of these cases were compiled. Statistical analysis was carried out using IBM SPSS version 25.0 statistical software.

Result: 158 euthyroid, 56 subclinical hypothyroid and 28 overt hypothyroid cases were included. >70% of hypothyroid and ~60% of control group was anemic. Normocytic anemia was reported in 80% (overt) and 60% (subclinical) hypothyroid anemics, rest were microcytic. Reduced levels of TIBC; all erythroid markers {hemoglobin, TRBC, color index (CI), MCV, MCH, MCHC and PCV}, and significant increase in serum iron were observed in both subclinical and overt hypothyroid cases compared to euthyroid. Reduction of Hb, PCV, MCH and CI were statistically significant. These four parameters exhibited significant negative correlation with serum TSH whereas serum iron showed a significant positive correlation.

Conclusion: Anemia cases (particularly treatment resistant ones) should be screened for thyroid abnormality. CBC should be carried out in all overt and subclinical hypothyroid cases.

Keywords: Color Index (CI); Mean Corpuscular Hemoglobin Concentration (MCHC); Subclinical Hypothyroidism (SCH); Total Iron Binding Capacity (TIBC); Thyroid stimulating hormone (TSH).

Introduction

The thyroid is the largest endocrine gland of human body. Microscopically, thyroid gland consists of number of spherical follicles, lined by follicular cells which may be low cuboidal to tall columnar in shape according to their degree of metabolic activity.^{1,2} Functionally, it has two types of cells: thyroid follicular cells (producing thyroid hormones or THs) and parafollicular (or C-cells) (secrete calcitonin).³ Thyroglobulin inside thyroid follicles (rich in amino acid tyrosine residues) store iodine as mono-iodo tyrosine (MIT) and di-iodo tyrosine (DIT), the inactive precursors of THs. Substitution of a second phenol moiety in place of phenolic hydrogen in tyrosine produces thyronine. Differential iodination at meta positions of two phenyl rings of thyronine leads to production of various thyroid hormones: the active form T3 (3, 5, 3'-triiodothyronine), major form thyroxine or T4 (3, 5, 3', 5'-tetraiodothyronine) and biologically inactive form reverse-T3 (3, 3', 5'-triiodothyronine).^{1,4} THs act as transcription factors via their nuclear receptors (TRa and TRb) mediating expression of various genes. Thus THs help in normal development, growth, differentiation and physiological functioning of most tissues. They also regulate the metabolic rate of various tissues, including hematopoietic tissues.^{4,6} THs are involved in hemoglobin production in adults as well as fetal hemoglobin maturation.⁷⁻⁹

Thyroid function tests include measurement of serum levels of THs (T3 and T4) and TSH. Accordingly patients are classified into euthyroid (both TSH and THs in normal reference range), hyperthyroid (low TSH and higher THs) and hypothyroid (higher TSH and lower THs).¹⁰⁻¹² Hypothyroidism is the most prevalent functional derangement of thyroid, caused chiefly by thyroid pathology (primary hypothyroidism >99.5%) and rarely (<5%) due to pituitary or hypothalamic pathology (secondary or central hypothyroidism). Hypothyroid cases also has been categorized as overt hypothyroid (TSH higher than 5.5 mIU/L and lower THs) and subclinical hypothyroid (TSH>4.0 mIU/L with THs, particularly thyroxine within normal reference range).^{3,5} Worldwide annual incidence of hypothyroidism has been estimated to be approximately 0.6 cases per men and 4.1 cases per 1000 women.¹³ Hypothyroidism prevalence is roughly 0.1% in males and 1-2% in females.¹⁴⁻¹⁶ Interestingly, subclinical hypothyroidism prevalence is much higher (4-10%) and more so among elderly (18%).¹⁷⁻²⁰

Thyroid hormones are being implicated to erythropoiesis via various mechanisms. THs induce erythropoietin (EPO) gene expression hence indirectly enhance erythropoiesis.²¹⁻²⁴ Under the direct mechanism, THs increase hypoxia inducible factor1 (HIF-1) repletion thus motivating various erythroid colonies (BFU-E, CFU-E) growth. This leads to hyper proliferation of immature erythroid progenitors thus enhancing erythropoiesis. THs augment RBC 2,3-DPG compactness, hence enhancing tissue oxygen delivery.^{4,6,25-33}

Anemia is generally defined as a reduction in either the number of red blood cells (RBC) and/or hemoglobin (Hb), resulting in reduced blood oxygen carrying capacity.^{34,35} It is very much prevalent in all parts of world, in many a places up to 10% of population being affected. Reproductive age group females and elderly are more prone to develop anemia.³⁵ As per World Health Organization (WHO) guidelines, Hb level <13.0 g/dL for men and is <12.0 g/dL for women is considered as diagnostic criteria for anemia.³⁵ According to red cell size/volume, anemia is classified into: normocytic anemia (mean corpuscular volume or MCV in the range of 80 to 100 fl or femtoliter), microcytic anemia (MCV <80 fl) and macrocytic anemia (MCV >100 fl).^{27,36,37} Most common cause for anemia is iron deficiency (microcytic hypochromic anemia) in developing countries followed by folate and/or cobalamine deficiency (macrocytic/megaloblastic/pernicious anemia), which is major cause in developed nations.^{38,39}

The associations of various types of thyroid disorders with hematological abnormalities have been reported since long.⁴⁰ The association of anemia with Grave's disease has already been demonstrated since 1979.⁴¹ Subclinical hypothyroid cases usually present with various hematological parameters abnormalities, particularly anemia.²² Reduced total RBC count in thyroidectomy cases was first reported by Horton et. al.⁴² All myeloid cell lines show hyperplasia in hyperthyroidism and hypoplasia in hypothyroidism.⁴³⁻⁴⁷ But anemia is not so commonly seen in hyperthyroidism as is erythrocytosis.^{41,48} Hypothyroidism has been reported to be associated with either anemia (in most cases) or immature erythroid progenitor proliferation.⁴² Among hypothyroid cases, anemia prevalence has been estimated to be ranging from 20% to 60%.⁴⁹ Though many varieties of anemia (normocytic, microcytic and macrocytic) are reported in hypothyroids; microcytic hypochromic (mimicking iron deficiency) anemia is the most common presentation.^{27,42,50} This phenomenon can

be attributed to the prevalence of low levels of iron, folate and/or vitamin B12 in the population (and so among hypothyroid cases).^{42,51} Pancytopenia is a rare immunologic presentation among hypothyroids, caused by decreased life span of thrombocytes and erythrocytes.⁵² All hematological abnormalities are reversible and normal levels of blood parameters are restored once euthyroid state is reached.^{4,53}

Iron is bound to pyrrole rings in number of hemoproteins. Some hemoproteins like hemoglobin and myoglobin act as oxygen carrier and many others like cytochrome oxidase, cytochrome P450s, electron transport proteins, catalase, peroxidase, etc. function as molecular oxygen activator. Total Iron Binding Capacity (TIBC) is the measure of iron reserve deficiency in the body.^{54,55} Ferritin is storage form of iron, mostly intracellular and sparsely found in plasma (normal reference range: 20-270 ng/ml).⁵⁶ It is a reliable marker of total body iron.⁴⁴ Its blood levels raise in conditions of rapid RBC turnover.^{57,58} Iron deficiency (ID) has been reported to reduce plasma THs by attenuating hepatic deiodinase activity, thus hampering peripheral T4 to T3 conversion.⁴³ Positive correlation of serum ferritin with plasma reverse-T3 concentration and T4/T3 ratio has been observed.^{31,41} Significant negative correlation of hemoglobin and serum TSH levels has been reported in Nepal.^{59,60} ID has been proved to reduce TRH induced TSH response⁴³ and TPO activity.⁶¹ Subjects with moderate to severe ID with(out) anemia have demonstrated upto 10% reduction in THs levels.⁶²⁻⁶⁵

Many studies have been conducted for accessing associations of various hematological parameters in various thyroid diseases. Most of these studies were conducted either in developed countries or in middle-east nations, very few in Africa and India. Thus we considered for looking into association of various indices of iron metabolism and erythrocyte associated parameters in (both subclinical and overt) hypothyroids in comparison to their normal counterparts.

Abbreviations

THs: Thyroid Hormones;
 TRH: Thyrotropin Releasing Hormone;
 EPO: Erythropoietin;
 TIBC: Total Iron Binding Capacity;
 RBC: Red Blood Cell;
 TRBC: Total RBC Count;
 WBC: White Blood Cell;
 TLC: Total Leukocyte Count;
 Hb: Hemoglobin;

DC: Differential Count;

ID: Iron deficiency;

TPC: Total Platelet Count;

MCV: Mean Corpuscular Volume;

PCV: Packed Cell Volume;

MCH: Mean Corpuscular Hemoglobin;

MCHC: Mean Corpuscular Hemoglobin Concentration.

NR: Normal Reference range

Materials and Methods


This is a retrospective cross-sectional study. Laboratory data of study participants were collected from laboratory data in Pathology department. Patient data of Thyroid Function Tests [serum free T3 (NR 3.1-5.9 pMol/L), free T4 (NR 0.7-2.7 ng/dl) and TSH (NR 0.35-5.50 mIU/L)]; Hematological parameters [Hemoglobin, Total RBC count (TRBC: NR 4.32-5.72 million cells/microLiter), Total Leukocyte count (TLC: NR 3000-10500 cells/microLiter), Total Platelet count (TPC: NR 1.5-4.0L/microLiter), Differential WBC Count(DC), Hematocrit, Mean Corpuscular Volume (MCV: NR 80-100 femtoLiter/RBC), Mean Corpuscular Hemoglobin (MCH: NR 27.5-33.2pg/RBC), Mean Corpuscular Hemoglobin Concentration (MCHC: NR 32-36 gm/dl)] alongside indices for iron metabolism [serum iron (NR 35-15 µg/dl), serum ferritin (NR 20-270 ng/ml) and TIBC(NR 252-479 µg/dl)] were collected. Those patients' medical records were also accessed retrospectively. Color Index (CI) was calculated as $\{(\%Hb)/(\%RBC)\}$ where $[\%Hb=(Hb*100)/14.5]$ and $[\%RBC=(TRBC*100)/5.0]$.⁷

All the hematological parameters and TIBC were measured in whole blood while rest of parameters was estimated in serum samples. TFT was performed by electrochemiluminescence immunoassay (eCLIA) technology. CBC was carried out using automated cell counter. The TSH reference range was considered as 0.03-5.5 µIU/ml. Thus patients with TSH level >5.5 µIU/ml alongside reduced serum T4 and/or T3 level were considered as (overt) hypothyroid. Patients with TSH ≤4.0 µIU/ml (and ≥0.03 µIU/ml) with normal serum THs were designated as euthyroid. Those patients with TSH >4.0 µIU/ml (and <5.5 µIU/ml) with normal thyroxin levels were considered as subclinical hypothyroid cases.

Exclusion Criteria

Table 1: Prevalence of Different Types of Anemia in Various Thyroid Disorders.

Thyroid_Disorder/ Anemia_Type	Microcytic	Normocytic	No_Anemia	Total
Euthyroid	20 (12.66%)	76 (48.10%)	62 (39.24%)	158 (100%)
Subclinical Hypothyroid	16 (28.57%)	24 (42.86%)	16 (28.57%)	56 (100%)
Overt Hypothyroid	4 (14.29%)	16 (57.14%)	8 (28.57%)	100%

**Fig. 1:** Prevalence of Different Types of Anemia in Various Thyroid Disorders:

Patients with known thyroid or hematological malignancy; or any other type of chronic disease were excluded.

Statistical Analysis

Kolmogorov-Smirnov test (N=242) was used to assess normality of parameters concerned. All the study parameters except serum iron, serum ferritin and TLC (Total Leukocyte Count) followed Gaussian distribution; thus was expressed as Mean \pm SD; compared by using Student's t-test (two groups) and one-way ANOVA (more than two groups); and correlation assessed by Pearson's correlation. Other three parameters, not following normal distribution, were expressed as Median (IQR); compared by using Mann-Whitney U test (two groups) and Kruskal Wallis test (more than two groups); and correlation assessed by Spearman Rank correlation. Chi Square test was employed for assessing comparison among proportions. IBM SPSS version 25.0 was used to carry out all statistical analyses.

Result

In this study, we considered register data of a particular time frame. Thus among 242

cases included (as per inclusion and exclusion criteria) 158 were euthyroid, 56 were subclinical hypothyroid and 28 were overt hypothyroid cases. All three groups were age-matched (p-value: 0.360) (Table 2). Serum iron, ferritin, TLC, neutrophil and lymphocyte were not following Gaussian distribution, thus compared using Kruskal Wallis test and correlation with other parameters accessed by Spearman Rank Correlation. Other parameters were following normal distribution, thus comparison among groups carried out using one-way analysis of variance (ANOVA) and correlation by Pearson's correlation.

Prevalence of various types of anemia in study population was analysed in accordance with thyroid profile status. It was observed that ~71.5% of patients in both subclinical and overt hypothyroid groups were anemic compared to ~60% of euthyroid (control) group. Among anemic patients, 20% presented with microcytic anemia and 80% were normocytic in both overt hypothyroidism and control groups. But in subclinical hypothyroid group anemic patients, 40% were microcytic and 60% were normocytic. The comparison of different types of anemia prevalence in different study groups was compared using Chi Square test, which showed that the differences were not statistically

Table 2: Comparison Among Three Groups

Parameters	Euthyroid (158) (A)	Subclinical (B) hypothyroid (56)	Overt (C) (28) hypothyroid	One-way ANOVA/KW test	
				F/KWH	p-value
Age	23.9 ± 3.5	25 ± 3.4	25.43 ± 4.68	1.032	0.360
fT3	2.56 ± 0.63	2.31 ± 0.98	2.29 ± 1.02	1.079	0.344
fT4	0.96 ± 0.32	1.02 ± 0.17	1.02 ± 0.48	0.303	0.739
Serum Iron	78.23 ± 36.24	99.5 (74.5-152.7)	87 (64-100)	7.112	0.029
TIBC	494.33 ± 68.29	490.29 ± 62	491.86 ± 51.18	0.025	0.976
Serum Ferritin	25 (17.4-53)	19.85 (12.4-25.9)	28 (16.2-58.2)	2.088	0.352
Hb	11.54 ± 1.38	10.5 ± 2.11	9.71 ± 1.21	6.924	0.002
TRBC	4.17 ± 0.51	4.01 ± 0.71	3.93 ± 0.24	1.140	0.324
CI	1.03 ± 0.12	0.97 ± 0.09	0.917 ± 0.115	3.859	0.024
MCV	84.77 ± 6.12	81.8 ± 6.45	80.5 ± 5.35	2.643	0.076
MCH	27.78 ± 2.42	26.17 ± 2.59	25.64 ± 1.74	4.657	0.012
MCHC	32.64 ± 1.54	32.06 ± 1.67	31.91 ± 1.62	1.356	0.263
PCV	35.62 ± 3.78	32.68 ± 5.22	31 ± 2.94	6.864	0.002
TLC	10.1 (8.8-11.5)	8.9 (7.52-10.5)	10.3 (9.4-13.1)	4.654	0.098
N	77 (73-82)	72.5 (68-77)	78 (72-81)	5.357	0.069
L	19 (14-23)	22 (18.5-25.2)	17 (13-24)	4.522	0.104
M	2.78 ± 1.42	3.71 ± 1.26	3.57 ± 1.39	3.319	0.040
TPC	196.33 ± 69.93	226.36 ± 84.1	232.57 ± 46.24	1.723	0.184

CI: Color Index, Sig. (2-tailed): p-value

Bonferroni post-hoc:

Hb: A and B=0.056, B and C=0.775, C and A=0.008, CI: A and B=0.270, B and C=1.000, C and A=0.060, MCH: A and B=0.071, B and C=1.000, C and A=0.081, PCV: A and B=0.036, B and C=1.000, C and A=0.012, M: A and B=0.072, B and C=1.000, C and A=0.472.

Table 3: Correlation Among Parameters:

Pearson's Correlation	Correlation Coefficient	p-value	Pearson's Correlation	Correlation Coefficient	p-value
TSH and fT3	-.117	.245	TSH and TIBC	.002	.986
TSH and fT4	-.011	.914	TSH and MCV	-.191	.057
TSH and Hb	-.319	.001	TSH and MCH	-.291	.003
TSH and TRBC	-.114	.257	TSH and MCHC	-.115	.253
TSH and PCV	-.296	.003	TSH and CI	-.270	.007
TSH and TPC	.135	.181			
Spearman Correlation	ρ	p-value	Spearman Correlation	ρ	p-value
TSH and s_iron	.364	<.001	TSH and s_ferritin	.108	.284
TSH and TLC	-.142	.159			

[Spearman ρ (serum iron, serum ferritin, TLC)] [Pearson's Correlation Coefficient: (Rest)]

significant. (Fig. 1, Table 1)

Study parameters were compared across three groups (euthyroid, subclinical hypothyroid and overt hypothyroid). Serum iron (KWH: 7.112, p=0.029); Hemoglobin (F: 6.924, p=0.002); CI (F: 3.859, p=0.024); MCH (F: 4.657, p=0.012); PCV (F: 6.864, p=0.002) and Monocyte count (F: 3.319, p=0.040) were found to statistically significantly differ among three groups. Bonferroni post-hoc

analysis (carried out with ANOVA) has shown statistically significant reduction of hemoglobin and PCV in overt hypothyroid cases compared to euthyroid. But only PCV had exhibited statistically significant reduction in subclinical hypothyroid group in comparison to euthyroid group. (Table 2)

Serum TSH level exhibited a significant positive correlation with serum iron level. In contrast significant negative correlation of serum TSH was

observed with hemoglobin, PCV, MCH and color index. (Table 3)

Discussion

Thyroid, the largest endocrine organ, is perhaps the most important endocrine gland in human as per functional perspectives.⁴ Thyroid hormones regulate the metabolic rate of various tissues, hematopoietic tissues inclusive.^{4,6} These hormones augment erythropoiesis both via direct and indirect (erythropoietin gene expression) mechanisms.^{21-24,26-33} Hypothyroidism is the most common thyroid dysfunction where blood levels of THs are reduced. Subclinical hypothyroidism is more prevalent than overt hypothyroidism.⁵ Subclinical hypothyroidism is associated with more complications and most of the patient progress to overt hypothyroidism in due course.⁵

Hypothyroidism has been reported to be associated with either anemia (mostly) or immature erythroid progenitor proliferation.⁴² Anemia prevalence among hypothyroids has been estimated to be falling between 20% and 60%.⁴⁹ According to our finding, >70% patients in both subclinical and overt hypothyroid groups were anemic compared to ~60% of euthyroid (control) group. Since Northern India is in the goiter belt and thus soil iodine deficiency may be the major contributing factor for higher prevalence. Also our study participant selection was by convenient sampling and may not be random enough and/or sufficient sample size to represent the true population.

Though normocytic, microcytic and macrocytic anemia, all types are reported in hypothyroids; microcytic hypochromic (mimicking iron deficiency) anemia is the most common presentation.^{27,35,50,66} But studies also reported preponderance of macrocytic anemia in hypothyroid cases.^{33,42,67} as well as both normo- and macrocytic anemia in hypothyroids.⁵ Our findings were majority of normocytic anemia (80% in overt and 60% in subclinical hypothyroids) with microcytic anemia in minority. None of macrocytic anemia cases reported in hypothyroids of our study. This indicates coexistence of iron deficiency in the population.

In hypothyroid cases, reduced levels of erythropoietin⁵, hemoglobin, TRBC, MCH and MCHC and raised MCV and PCV were reported.^{4,33} Other study reported only MCV increased and no difference in Hb or PCV in hypothyroids compared to controls.⁶⁸ One study also shows no significant

difference in all these hematological parameters in hypothyroid cases.⁶⁹ In our study, we report reduced levels of all erythroid markers {hemoglobin, TRBC, color index (CI), MCV, MCH, MCHC and PCV} and TIBC where as significant increase in serum iron among hypothyroids. Among reduced parameters, reduction of Hb, PCV, MCH and CI were statistically significant. Prevalence of anemia in hypothyroids may be a physiological adaptation to the decrease in tissue oxygen requirement owing to lower metabolic rate in absence of sufficient THs.⁵ All these alterations in hematological parameters normalize once appropriate hormonal replacement is instituted.⁷⁰ We also report significant negative correlation of serum TSH with Hb, CI, PCV and MCH and significant positive correlation of serum TSH and serum iron.

Conclusion

Both subclinical and overt hypothyroidisms have direct effects on all red cell indices. Thus all patients with hypothyroid state should be screened at regular interval for development of hematological (particularly erythroid indices) abnormality, hence appropriate correction in treatment regime can be instituted at an earlier stage. All cases of anemia (particularly treatment resistant ones) should be screened for thyroid abnormality as subclinical conditions are very much prevalent in our population.

Conflict of Interest: The authors declare no conflict of interest.

Acknowledgement: We thank our patients and acknowledge staffs for their support.

Funding: Being a retrospective study based on previous records, no fund was utilized.

References

1. Winter WE, Schatz DS and Bertholf RL. The Thyroid: Pathophysiology and Thyroid Function Testing. In: Burtis CA, Ashwood ER and Burns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Reed Elsevier India Pvt. Ltd. Elsevier. 2012; 55: 1905-44.
2. Wartofsky L. The thyroid gland. In: Becker KL (ed) Principles and practice of endocrinology and metabolism. Lippincott Williams and Wilkins, Philadelphia. 308-401.
3. Bliss RD, Gauger PG, Delbridge LW. Surgeon's approach to the thyroid gland: surgical anatomy and the importance of technique. World J Surg 2000;

- 8: 891-7.
4. Dorgalaleh A, Mahmoodi M, Varmaghani B, Kiani node F, Saeedi Kia O, Alizadeh Sh, et. al. Effect of Thyroid Dysfunctions on Blood Cell Count and Red Blood Cell Indice. *Iranian Journal of Pediatric Hematology Oncology*. 2013; 3(2): 73-7.
 5. Bashir H, Bhat MH, Farooq R, Majid S, Shoib S, Hamid R, et. al. Comparison of hematological parameters in untreated and treated subclinical hypothyroidism and primary hypothyroidism patients. *Medical Journal of Islamic Republic of Iran*. 2012; 26(4): 172-8.
 6. Golde DW, Bersch N, Chopra IJ and Cline MJ. Thyroid hormones stimulate erythropoiesis in vitro, *The British Journal of Haematology*. 1977; 37 (2): 173-7.
 7. Koibuchi N, Chin WW. Thyroid hormone action and brain development. *Trends Endocrinol Metab*. 2000; 11(4): 123-8.
 8. Ahmed OM, El-Gareib AW, El-Bakry AM, Abd El-Tawab SM, Ahmed RG. Thyroid hormones states and brain development interactions. *Int J Dev Neurosci*. 2008; 26(2): 147-209.
 9. Saranac L, Zivanovic S, Bjelakovic B, Stamenkovic H, Novak M, Kamenov B. Why is the thyroid so prone to autoimmune disease? *Horm Res Paediatr*. 2011; 75(3): 157-65.
 10. Pimentel L, Hansen KN. Thyroid disease in the emergency department: a clinical and laboratory review. *J Emerg Med*. 2005; 2: 201-9.
 11. Mistry N, Wass J, Turner MR. When to consider thyroid dysfunction in the neurology clinic. *Pract Neurol*. 2009; 3: 145-56.
 12. Laurberg P, Andersen S, Bulow P, Carle A. Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment. *Drugs Aging* 2005; 1: 23-38.
 13. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty year follow-up of the Whickham Survey. *Clin Endocrinol* 1995; 43:55-68.
 14. Tunbridge WMG, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et. al. The spectrum of thyroid disease in a community: The Whickham survey. *Clin Endocrinol(Oxf)*.1977;7:481-93.
 15. Vanderpump MP, Tunbridge WM. The epidemiology of thyroid disease. In: Braverman LE, Utiger RD, eds. *The Thyroid*, 9th edn, Philadelphia: Lippencott-Raven 1996; p. 474-82.
 16. Helfand M, Redfern CC. Clinical Guideline Part 2: Screening for thyroid disease: An update. *Ann Intern Med* 1998; 129:144-58.
 17. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. *Arch Intern Med* 2000; 160:526-34.
 18. Sawin CT, Chopra D, Azizi F, Mannix JE, Bacharach P. The aging thyroid. Increased prevalence of elevated serum thyrotropinlevels in the elderly. *JAMA* 1979; 242:247-50.
 19. Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years. A study in an urban U.S. community. *Arch Intern Med* 1990; 150:785-7.
 20. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANESIII). *J Clin Endocrinol Metab* 2002; 87:489-99.
 21. Schindhelm RK, et. al. Thyroid hormones and erythrocyte indices in a cohort of euthyroid older subjects. *Eur. J. Intern. Med*. 2013; 24 (3): 241-4.
 22. Ashraf TS, et al. Chronic anemia and thyroid function. *Acta Biomed.: AteneiParmensis*. 2017; 88 (1): 119.
 23. Fandrey J, Pagel H, Frede S, Wolff M andJelkmann W. Thyroid hormones enhance hypoxia-induced erythropoietin production in vitro, *Experimental Hematology*. 1994; 22 (3): 272-7.
 24. Dainiak N, Sutter D andKreczko S. L-triiodothyronine augments erythropoietic growth factor release from peripheral blood and bone marrow leukocytes. *Blood*. 1986; 68(6):1289-97.
 25. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. *Clin Chest Med*. 2003; 24(4): 607-22.
 26. Perrin MC, Blanchet JPandMouchiroud G. Modulation of human and mouse erythropoiesis by thyroid hormone and retinoic acid: evidence for specific effects at different steps of the erythroid pathway. *Hematology and Cell Therapy*. 1997; 39: 19-26.
 27. Szczepanek-Parulska E, Hernik A andRuchala M. Anemia in thyroid diseases. *Pol. Arch. Intern. Med*. 2017; 127 (5): 352-60.
 28. Malgor LA, Blanc CC, Klainer E, et. al. Direct effects of thyroid hormones on bone marrow erythroid cells of rats. *Blood*.1975; 45 (5): 671-9.
 29. Mackenzie GM. Anemia in hypothyroidism. *JAMA*. 1926; 86(7): 462-64.
 30. Leberbauer C,Boulme F, Unfried G, Huber J, Beug H and Mullner EW. Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. *Blood*. 2005; 105: 85-94.
 31. Eftekhari MH, Keshavarz SA, Jalali M, Saadat N, Seyasi F, Eshraghian MR Elguero E. The relationship between iron status and thyroid hormone concentration in iron-deficient adolescent Iranian girls. *Asia Pac J Clin Nutr* 2006; 15: 50-5.
 32. Schroeder C, Gibson L, Zenke M and Beug H. Modulation of normal erythroid differentiation by

- the endogenous thyroid hormone and retinoic acid receptors: a possible target for *verba* oncogene action. *Oncogene*. 1992; 7 (2): 217-27.
33. Kawa MP, Grymula K, Paczkowska E, Baskiewicz-Masiuk M, Dabkowska E, Koziol M, et al. Clinical relevance of thyroid dysfunction in human haematopoiesis: biochemical and molecular studies. *Eur J Endocrinol*. 2010; 162(2): 295-305.
 34. Thorley-Lawson DA. Basic virological aspects of Epstein-Barr virus infection. *Semin Hematol*. 1988; 25(3):247-60.
 35. Ahmed SS and Mohammed AA. Effects of thyroid dysfunction on hematological parameters: Case controlled study. *Annals of Medicine and Surgery*. 2020; 57: 52-5.
 36. Tefferi A. Anemia in adults: a contemporary approach to diagnosis, *Mayo Clinic Proceedings*, Elsevier, 2003.
 37. W.H. Organization, Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity, World Health Organization, 2011.
 38. Balarajan Y, Ramakrishnan U, Ozaltin E, Shankar AH and Subramanian SV. Anemia in low-income and middle-income countries. *Lancet*. 2011 Dec 17; 378 (9809): 2123-35. Doi: 10.1016/S0140-6736(10)62304-5. Epub 2011 Aug 1.
 39. Kassebaum NJ, GBD 2013 Anemia Collaborators. The Global Burden of Anemia. *Hematol. Oncol. Clin. North Am*. 2016 Apr; 30(2):247-308. doi: 10.1016/j.hoc.2015.11.002.
 40. Iddah MA, Macharia BN, Ng'wena AG, Keter A. and Ofula AVO. Thyroid Hormones and Hematological Indices Levels in Thyroid Disorders Patients at Moi Teaching and Referral Hospital, Western Kenya. *ISRN Endocrinology*. 2013; 385940: 1-6. doi: 10.1155/2013/385940.
 41. Eftekhari MH, Keshavarz SA, Jalali M, Saadat N, Seyasi F, Eshraghian MR. Thyroid Hormones Status in Iron Deficient Adolescent Girls. *Iran J Med Sci* 2003; 28: 161-5.
 42. Horton L, Coburn RJ, England JM and Himsworth RL. The haematology of hypothyroidism. *Quarterly Journal of Medicine*. 1976; 45 (177): 101-23.
 43. Brigham DE, Beard JL. Effect of thyroid hormone replacement in iron-deficient rats. *Am J Physiol*. 1995; 269(5 Pt 2):R1140-7.
 44. Meyron-Holtz EG, Moshe-Belizowski S, Cohen LA. A possible role for secreted ferritin in tissue iron distribution. *J Neural Transm (Vienna)*. 2011;118(3):337-47. doi:10.1007/s00702-011-0582-0.
 45. Das KC, Mukherjee M, Sarkar TK, Dash RJ, Rastogi GK. Erythropoiesis and erythropoietin in hypo- and hyperthyroidism. *J Clin Endocrinol Metab*. 1975; 40(2): 211-20.
 46. A. R. Axelrod and L. Berman. "The bone marrow in hyperthyroidism and hypothyroidism." *Blood*. 1951; 6 (5): 436-53.
 47. Fein HG, Rivlin RS. Anemia in thyroid diseases. *Med Clin North Am*. 1975; 59(5): 1133-45.
 48. Corrocher R, Querena M, Stanzial AM and de Sandre G. Microcytosis in hyperthyroidism: haematological profile in thyroid disorders. *Haematologica*. 1981; 66(6):779-86.
 49. Kosenli A, Erdogan M, Ganidagli S, Kulaksizoglu M, Solmaz S, Kosenli O, et al. Anemia frequency and etiology in primary hypothyroidism. *Endocr Abstr* 2009; 20: 140.
 50. Mackenzie GM. Anemia in hypothyroidism. *JAMA*. 1926; 86(7): 462-64.
 51. Hines JD, Halsted CH, Griggs RC and Harris JW. Megaloblastic anemia secondary to folate deficiency associated with hypothyroidism. *Annals of Internal Medicine*. 1968; 68(4):792-805.
 52. Lima CS, Zantut Wittmann DE, Castro V, Tambascia MA, Lorand-Metze I, Saad ST, et al. Pancytopenia in untreated patients with Graves' disease. *Thyroid* 2006; 16 (4): 403-9.
 53. Perlman JA, Sternthal PM. Effect of 131I on the anemia of hyperthyroidism. *Journal of Chronic Diseases*. 1983; 36 (5): 405-12.
 54. Lynch S, Pfeiffer CM, Georgieff MK, Brittenham G, Fairweather-Tait S, Hurrell RF, McArdle HJ and Raiten DJ. Biomarkers of Nutrition for Development (BOND)-Iron Review. *J. Nutr*. 2018 Jun; 148(Suppl 1): 1001S-1067S. doi: 10.1093/jn/nxx036.
 55. Pfeiffer CM, Looker AC. Laboratory methodologies for indicators of iron status: strengths, limitations and analytical challenges. *Am J Clin Nutr*. 2017 Dec; 106(Suppl 6): 1606S-1614S. doi: 10.3945/ajcn.117.155887.
 56. Mostafa GG, Zahran FE, Omer SA, Ibrahim A and Elhakeem H. The Effect of Serum Ferritin Level on Gonadal, Prolactin, Thyroid Hormones, and Thyroid Stimulating Hormone in Adult Males with Sickle Cell Anemia. *Journal of Blood Medicine*. 2020; 11: 27-32.
 57. Akinbami AA, Dosunmu AO, Adediran AA, et al. Serum ferritin levels in adults with sickle cell disease in Lagos, Nigeria. *J Blood Med*. 2013;4:59-63. doi:10.2147/JBM.S42212
 58. Makulo JR, Itokua KE, Lepira RK, et al. Magnitude of elevated iron stores and risk associated in steady-state sickle cell anemia Congolese children: a cross-sectional study. *BMC Hematol*. 2019;19 (3). doi:10.1186/s12878-019-0134-7.
 59. Khatiwada S, Lamsal M, Gelal B, Gautam S, Nepal AK, Brodie D, Baral N. Anemia, Iron Deficiency and Iodine Deficiency among Nepalese School Children. *Indian J Pediatr* 2016; 83: 617-21.
 60. Khatiwada S, Gelal B, Baral N, Lamsal M. Association between iron status and thyroid function in Nepalese children. *Thyroid Res* 2016; 9: 2 doi: 10.1186/ s13044-016-0031.
 61. Hess SY, Zimmermann MB, Arnold M, Langhans W,

- Hurrell RF. Iron deficiency anemia reduces thyroid peroxidase activity in rats. *J Nut.* 2002;132(7):1951-5.
62. Beard J, Green W, Miller L, Finch C. Effect of iron-deficiency anemia on hormone levels and thermoregulation during cold exposure. *Am J Physiol* 1984; 247: R114-R119.
63. Martinez-Torres C, Cubeddu L, Dillman E, Brengelmann GR, Leets I, Layrisse M, Johnson DG, Finch C. Effect of exposure to low temperature on normal and iron - deficient subjects. *Am J Physiol* 1984; 246; R380-R383.
64. Beard JL, Borel MJ, Derr J. Impaired thermoregulation and thyroid function in iron-deficiency anemia. *Am J Clin Nutr* 1990; 52: 813-9.
65. Beard JL, Tobin BW, Smith SM. Effects of iron repletion and correction of anemia on norepinephrine turnover and thyroid metabolism in iron deficiency. *Proc Soc Exp Biol Med* 1990; 193: 306-12.
66. Jafarzadeh A, et. al. Immunological and hematological changes in patients with hyperthyroidism or hypothyroidism *Clin. Investig. Med.* 2010; E271-E279.
67. Takahashi SI, Conti M, Van-Wyk JJ. Thyrotropin potentiation of insulin-like growth factor-I dependent deoxyribonucleic acid synthesis in FRTL-5 cells: mediation by an autocrine amplification factor (s). *Endocrinology.* 1990; 126 (2): 736-45.
68. Geetha J, Srikrishna R. Role of red blood cell distribution width (rdw) in thyroid dysfunction. *Int J Biol Med Res.* 2012; 3(2): 1476-8.
69. Demet S and Ilker S. Is there any link between a kind of Thyrocyte Dysfunction, Hypothyroidism and Inflammatory Hematologic parameters in the cases having the benign Thyroid nodules? A 5-year single-center experience. *Sanamed.* 2018; 13(1): 35-40. doi: 10.24125/sanamed.v13i1.211.
70. Montagnana M, Lippi G, Targher G, Salvagno GL and Guidi GC. The red blood cell distribution width is associated with serum levels of thyroid stimulating hormone in the general population. *Int J Lab Hematol.* 2009; 31: 581-2.

